Authera_Still8_0051.png
video_fallback_2000px.jpg

Authera is a pre-clinical-stage biotechnology company dedicated to the discovery and development of novel therapeutic biologics.

A high-end unique technology platform guiding design and selection

Our know-how is based on an in-depth molecular and cellular understanding of crucial biological processes, involving interactions between the neonatal Fc receptor (FcRn) and its ligands, IgG antibodies and albumin.

Our platform combines unique biochemical and cellular assays with state-of-the-art in vivo models, to guide pre-clinical design and selection.

Authera - working at the lab

The platform

Authera has two lead pre-clinical development programs.

Pre-clinical pipeline

AuT-1

Focus area

Exudative eye diseases

Partner with

AuT-2

Undisclosed

video_fallback2_2000px.jpg

Business

Authera is science-driven, as we learn by nature.

We strongly believe in partnership with academia, biotech and pharmaceutical industry.

Authera has the expertise needed to guide design and selection of FcRn-binding molecules. As such, a partnership with us will educate and de-risk product development towards clinical evaluation.

Simone Mester, PhD

Team

Simone Mester, PhD

Torleif T. Gjølberg, PhD

CEO & Co-founder

Torleif T. Gjølberg, PhD

Jan Terje Andersen, PhD

CSO & Co-founder

Jan Terje Andersen, PhD

Inger Sandlie, PhD

Chairman & Co-founder

Inger Sandlie, PhD

Board member & Co-founder

Gaia Calamera, PhD

Senior Scientist

Eirik Sundlisæter, MD PhD

Scientist

Jenny Skjermo Telstad, MSc

Research Assistant

Support